Gastric low-grade mucosal-associated lymphoid tissue-lymphoma: Helicobacter pylori and beyond
Gastric low-grade mucosal-associated lymphoid tissue-lymphoma: Helicobacter pylori and beyond作者机构：Gastroenterology and Digestive Endoscopy"Nuovo Regina Margherita"Hospital00153 RomaItaly Francesco PerriGastroenterology and Digestive Endoscopy"Casa Sollievo della Sofferenza"HospitalIRCCS71013 San Giovanni Rotondo(FG)Italy
出 版 物：《World Journal of Gastrointestinal Oncology》 (世界胃肠肿瘤学杂志（英文版）（电子版）)
年 卷 期：2010年第2卷第4期
页 面：181-186页
核心收录：
学科分类：1002[医学-临床医学] 100214[医学-肿瘤学] 10[医学]
主 题：Mucosal-associated lymphoid tissue Therapy Helicobacter pylori Gastric lymphoma Predictive factors Endoscopy Clinical presentation
摘 要：The stomach is the most frequently involved site for extranodal lymphomas,accounting for nearly two-thirds of all gastrointestinal cases.It is widely accepted that gastric B-cell,low-grade mucosal-associated lymphoid tissue(MALT)-lymphoma is caused by Helicobacter pylori(H.pylori)infection.MALT-lymphomas may engender different clinical and endoscopic patterns.Often,diagnosis is confirmed in patients with only vague dyspeptic symptoms and without macroscopic lesions on gastric mucosa.H.pylori eradication leads to lymphoma remission in a large number of patients when treatment occurs at an early stage(Ⅰ-Ⅱ1).Neoplasia confined to the submucosa,localized in the antral region of the stomach,and without API2-MALT1 translocation,shows a high probability of remission following H.pylori eradication.When both bacterial infection and lymphoma recur,further eradication therapy is generally effective.Radiotherapy,chemotherapy and,in selected cases,surgery are the available therapeutic options with a high success rate for those patients who fail to achieve remission,while data on immunotherapy with monoclonal antibodies (rituximab)are still scarce.The 5-year survival rate is higher than 90%,but careful,long-term follow-up is required in these patients since lymphoma recurrence has been reported in some cases.
维普期刊数据库